Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
Albertsons has the scale, loyalty data, Own Brands, and cash flow to rebuild a standalone grocery thesis after the failed Kroger deal. The tension is whether low-margin retail, pharmacy headwinds, labor costs, debt, opioid charges, and capital returns leave en
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for AC Immune SA.
OpenPhilip Morris generated $40.6 billion of 2025 revenue and $12.2 billion of operating cash flow, but the investment case depends on whether smoke-free growth, pricing, regulation and leverage can keep offsetting the structural decline and social risk of cigaret
OpenHershey reported FY2025 revenue of $11.7 billion, gross profit of $3.9 billion, operating income of $1.4 billion and Q1 2026 revenue of $3.1 billion. The thesis depends on cocoa-cost inflation, pricing power, brand demand, inventory control, cash conversion an
OpenAgencia Comercial Spirits Ltd came public as a Taiwan whisky importer, then disclosed a 2026 AI infrastructure pivot with a non-binding US$120M server LOI, a US$14.55M PIPE, Indonesian power commitments and a five-year services agreement that may represent up
OpenAcme United looks like a sleepy tools business until the filing mix shows first aid at roughly two-thirds of sales, a new My Medic deal, tariff pain, rising debt, and a customer-concentration test.
OpenOfficial-source baseline for Ambev using SEC submissions, SEC company facts, the FY2025 Form 20-F, Q1 2026 Form 6-K results materials, and official peer/controller filing context.
OpenAurora is trying to leave the worst cannabis-stock habits behind: Q3 FY2026 medical cannabis revenue set a record, management is exiting weaker Canadian consumer lanes, and the balance sheet has cash. The catch is that IFRS losses, Bevo restructuring, internal
OpenAC Immune has partner-backed Alzheimer's programs, a Parkinson's active immunotherapy readout, a new NLRP3 Phase 1 asset, and CHF 74.8 million of Q1 2026 cash resources. The hard question is whether 2026 milestones can turn platform promise into partner commit
OpenTag facets appear after tag usage counts are rebuilt.